bortezomib reddy 3,5 mg prášok na injekčný roztok
reddy holding gmbh, nemecko - bortezomib - 44 - cytostatica
lenalidomid grindeks 25 mg trvdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 20 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 15 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 10 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 7,5 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 5 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
lenalidomid grindeks 2,5 mg tvrdé kapsuly
as grindeks, lotyšsko - lenalidomid - 59 - immunopraeparata
darzalex
janssen-cilag international n.v. - daratumumab - viacnásobný myelóm - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinácii s bortezomib, talidomid a dexamethasone na liečbu dospelých pacientov s novo diagnostikovanou myelómom je mladších, ktorí majú nárok na autológne transplantácii kmeňových buniek. v kombinácii s lenalidomide a dexamethasone, alebo bortezomib a dexamethasone, na liečbu dospelých pacientov s mnohopočetným myelómom, ktorí dostali aspoň jeden pred terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. ako monotherapy na liečbu dospelých pacientov s relapsed a žiaruvzdorné myelómom je mladších, ktorých pred terapia súčasťou proteasome inhibítor a imunomodulačné agent a ktorí preukázali progresii ochorenia na poslednej terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
sandimmun 50 mg/ml
novartis slovakia s.r.o., slovensko - cyklosporín - 59 - immunopraeparata